The light from the screens are TOXIC for your eyes. This is a proven in-vitro and in-vivo problem, the high intensity light generated by LED screens can damage the retina even in moderate use.
Reticare is the only solution that has proven scientifically that can reduce risks very intensely.
*Photomontage performed to explain the magnifying image.
“I know it [Reticare] was the best choice for my MacBookPro, especially for my eyes.”
"There are computers I can use now that I could never use before.It's like magic"
“My whole family has Reticare eye protectors on all of our devices. Thank you for this wonderful product to save our eyes. Forever grateful!!”
“As an MBA student, I spend at least 10 hours every day in front of my computer. I recommend this product to everybody who uses screens in their daily life!”
"Wow, I wasn't expecting such a quick response to my questions – thank you! I can tell it makes a difference just by holding it in front of the screen so I really look forward to using it!"
Recent studies confirm that light from device screens can increase retinal cell death by 23%. This means the loss of approximately a quarter of vision.
The studies by the Complutense University of Madrid about avoidable blindness has proven that Reticare reduces the risks to the retina that can be caused by light emitted through electronic device screens such as smartphones, tablets, laptops and monitors.
Reticare is the worldwide leader in eye protection against high-energy light emitted from screen displays to prevent significant risks to your vision. 350,000 people already use the only eye protector endorsed by the scientific community.
Reticare is a young, contemporary company with a big mission: saving the world from a global vision crisis. Reticare is one of the worldwide main players and advisor for many governments and institutions on the topic of prevention from the risks of high energy light emitted from device screens.
with Reticare you sleep longer and better, improving your focus at work
Reduces the risks of early onset central vision blindness
Reticare's evidence is documented in more than 120 studies